Based on the positive results of preclinical studies examining the combination of selinexor and BTK inhibitors, ref. [40] a recent phase I clinical trial examined the combination of selinexor and daily BTK inhibitor ibrutinib in 33 patients with R/R NHL and chronic lymphocytic leukemia (CLL) [63]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.